Ryvu Therapeutics ROA
The Return on Assets (ROA) of Ryvu Therapeutics (RVU.WA) as of Nov 5, 2026 is -45.10 %. In the previous year, Return on Assets (ROA) was -29.42 % — a change of 53.31% (lower).
Get this data via API
Financial Data API
ROA
-45.10 %
YoY
53.31%
Last updated:
In 2025, Ryvu Therapeutics's return on assets (ROA) was -45.10 %, a 53.31% increase from the -29.42 % ROA in the previous year.
The Ryvu Therapeutics ROA history
3 Years
10 Years
25 Years
Max
| YEAR | ROA | YoY |
|---|---|---|
| -45.10 % | +53.31% | |
| -29.42 % | +28.78% | |
| -22.85 % | +29.51% | |
| -17.64 % | -48.96% | |
| -34.56 % | +222.44% | |
| -10.72 % | -45.55% | |
| -19.68 % | +47,237.31% | |
| -0.04 % | -100.67% | |
| 6.19 % | +102.67% | |
| 3.05 % | -68.24% | |
| 9.61 % | -55.97% | |
| 21.83 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Ryvu Therapeutics Stock analysis
ROA Details
Understanding Ryvu Therapeutics's Return on Assets (ROA)
Ryvu Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Ryvu Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Ryvu Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Ryvu Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Ryvu Therapeutics stock
Return on Assets (ROA) of Ryvu Therapeutics is -45.10 % in 2025.
Return on Assets (ROA) of Ryvu Therapeutics changed from -29.42 % to -45.10 %, representing a 53.31% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Return on Assets (ROA) Ryvu Therapeutics since 2006 – with annual values, charts, and detailed analysis.
Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Ryvu Therapeutics with sector peers and the industry average to assess whether it is attractive.
To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Profitability — Ryvu Therapeutics
All Key Metrics — Ryvu Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth